<div id="readability-page-1"><p>Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) Director Kevin Mclaughlin bought 50,000 shares of the stock in a transaction dated Wednesday, November 19th. The shares were acquired at an average cost of $2.50 per share, for a total transaction of $125,000.00. Following the completion of the acquisition, the director directly owned 50,000 shares of the company's stock, valued at approximately $125,000. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website.</p><h2>Invivyd Stock Performance</h2><p>Shares of IVVD stock traded down $0.10 during trading on Thursday, hitting $2.40. The company had a trading volume of 4,802,679 shares, compared to its average volume of 7,971,830. The firm has a market capitalization of $559.50 million, a P/E ratio of -5.11 and a beta of 0.64. Invivyd, Inc. has a one year low of $0.35 and a one year high of $3.07. The stock's 50-day moving average price is $1.64 and its 200 day moving average price is $1.09. </p><p>Invivyd (NASDAQ:IVVD - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.06) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.01). The company had revenue of $13.13 million for the quarter, compared to the consensus estimate of $12.00 million. Invivyd had a negative return on equity of 92.97% and a negative net margin of 119.63%. On average, research analysts anticipate that  Invivyd, Inc. will post -1.64 earnings per share for the current fiscal year. </p><h2>Hedge Funds Weigh In On Invivyd</h2><p>A number of institutional investors have recently added to or reduced their stakes in the stock. Catalyst Funds Management Pty Ltd acquired a new stake in  Invivyd in the second quarter valued at approximately $27,000.  Vanguard Personalized Indexing Management LLC lifted its stake in shares of  Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock valued at $29,000 after acquiring an additional 28,146 shares during the last quarter.  Bank of America Corp DE lifted its stake in shares of  Invivyd by 330.5% in the 3rd quarter. Bank of America Corp DE now owns 49,252 shares of the company's stock valued at $54,000 after acquiring an additional 37,811 shares during the last quarter.  Nuveen LLC acquired a new stake in shares of  Invivyd during the 1st quarter valued at $65,000.  Finally, XTX Topco Ltd bought a new stake in  Invivyd during the 1st quarter worth $66,000. 70.36% of the stock is currently owned by institutional investors and hedge funds. </p><h2>Analysts Set New Price Targets</h2><p>IVVD has been the subject of several recent analyst reports. Weiss Ratings  reaffirmed a &#34;sell (e+)&#34; rating on shares of Invivyd in a research report on Friday, October 31st. Zacks Research raised shares of Invivyd from a &#34;strong sell&#34; rating to a &#34;hold&#34; rating in a report on Thursday, November 13th. HC Wainwright lifted their price objective on shares of Invivyd from $5.00 to $10.00 and gave the company a &#34;buy&#34; rating in a research note on Friday, October 31st. Cantor Fitzgerald began coverage on shares of Invivyd in a research report on Monday, October 6th. They set an &#34;overweight&#34; rating and a $10.00 price objective for the company. Finally, D. Boral Capital raised their target price on Invivyd from $1.00 to $2.00 and gave the company a &#34;buy&#34; rating in a report on Monday, October 6th. Three investment analysts have rated the stock with a Buy rating, one  has issued  a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat, the company  has an average rating of &#34;Hold&#34; and a consensus price target of $7.33.</p><p><b>View Our Latest Research Report on IVVD</b></p><h2>About Invivyd</h2> (Get Free Report)<p>Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.</p><h2>See Also</h2><ul><li>Five stocks we like better than Invivyd</li><li>What is a Dividend King? </li><li>Joby and Archer Forge a New Strategic Chapter in the UAE</li><li>The Basics of Support and  Resistance</li><li>3 Speculative Stocks to Sell Before the Bottom Drops Out</li><li>What is a Bond Market Holiday? How to Invest and Trade</li><li>The Off-Price Retail King? Why TJX Looks Ready to Break Out</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVZWRA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SVZWRA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Invivyd Right Now?</h2><p>Before you consider Invivyd, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.</p><p>While Invivyd currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

IVVD

<p>Invivyd, Inc. Director Kevin Mclaughlin acquired 50,000 shares at $2.50 each, totaling $125,000. This transaction, disclosed in an SEC filing, marks a significant increase in his ownership. Invivyd's stock performance shows a slight decrease, trading at $2.40. Analysts have mixed ratings, with a consensus price target of $7.33. The company focuses on antibody-based solutions for infectious diseases.</p>

Invivyd (NASDAQ:IVVD) Director Kevin Mclaughlin Acquires 50,000 Shares